^
Association details:
Evidence:
Evidence Level:
Resistant: A1 - Approval
New
Source:
Excerpt:
Vectibix is not indicated for the treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS and hereafter is referred to as “RAS.
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab.
Evidence Level:
Resistant: B - Late Trials
Title:

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Published date:
09/04/2015
Excerpt:
We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer...: Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Patients with RAS mutations were unlikely to benefit from panitumumab. Patients with RAS mutations were unlikely to benefit from panitumumab-FOLFIRI.
Secondary therapy:
FOLFIRI
DOI:
10.1158/1078-0432.CCR-15-0526
Trial ID: